Carbohydrate (i.e., Saccharide Radical Containing) Doai Patents (Class 514/23)
  • Patent number: 11666590
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: June 6, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Odd-Erik Johansen, Eric Williams Mayoux, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z.I. Cherney, Bruce A. Perkins
  • Patent number: 11660308
    Abstract: The present invention relates to solid oral pharmaceutical compositions comprising amorphous dapagliflozin. The invention further relates to a process for the preparation of the said pharmaceutical compositions. The said compositions are administered orally for the treatment of diabetes mellitus. The said compositions provide the desired immediate release of dapagliflozin and were found to be stable under accelerated conditions.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: May 30, 2023
    Assignee: INVENTIA HEALTHCARE LIMITED
    Inventors: Vaibhavi Shah, Vijayendrakumar Redasani, Anant Ghongade
  • Patent number: 11643430
    Abstract: There is provided with a porphyrin compound represented by Formula (I) or a salt thereof; where A is a linking group represented as —X—NHCO— where X is a C1 to C6 alkylene group, each of R1, R2, R4, R5, R7, R8, R10, and R11 is a hydrogen atom, each of R3, R6, and R9 is a substituent of Formula; R12 is selected from a group of substituents represented by Formulae, R13 is a sulfo group, Ra, Rb, and Rc are substituents independently selected from C1 to C6 alkyl groups, and Rd is a hydrogen atom or a C1 to C6 alkyl group, and Rx is a substituent represented by General Formula. The porphyrin compound is useful as a cancer therapeutic agent, photosensitizer and fluorescent probe.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: May 9, 2023
    Assignees: M.T.3, INC., NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY
    Inventors: Hiroaki Horiuchi, Masahiko Oshige, Ichiro Matsuo, Tetsuo Okutsu, Shinji Katsura, Toshitada Yoshihara, Seiji Tobita, Fumio Sugawara, Kengo Sakaguchi
  • Patent number: 11629344
    Abstract: The present disclosure provides compositions, methods, systems, and devices for polynucleotide processing. Such polynucleotide processing may be useful for a variety of applications, including polynucleotide sequencing.
    Type: Grant
    Filed: July 8, 2022
    Date of Patent: April 18, 2023
    Assignee: 10X GENOMICS, INC.
    Inventors: Benjamin Hindson, Christopher Hindson, Michael Schnall-Levin, Kevin Ness, Mirna Jarosz, Serge Saxonov
  • Patent number: 11612555
    Abstract: An oral care composition for alleviating dentin hyperesthesia is disclosed. The oral care composition includes a peptide consisting of an amino acid sequence of the following Formula 1: K—Y-R1-R2-R3-R4-R5-R6-R7-R8??(Formula 1) wherein R1 is arginine (R), lysine (K) or glutamine (Q); R2 is arginine (R) or glutamine (Q); R3, R4, and R5 are arginine (R) or lysine (K), respectively; R6 is asparagine (N) or serine(S); and R7 and R8 are lysine (K) or tyrosine (Y), respectively.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: March 28, 2023
    Assignee: HYSENSBIO
    Inventors: Joo Hwang Park, Ji Hyun Lee
  • Patent number: 11583593
    Abstract: The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: February 21, 2023
    Assignee: Synthis Therapeutics, Inc.
    Inventor: Dori A. Thomas-Karyat
  • Patent number: 11560399
    Abstract: The invention relates to a process to prepare a compound of the following formula (I): (I), in which P represents a protective group of a hydroxyl function which is a —COR1 group with R1 representing an aryl or a (C1C6)alkyl, R represents a hydrogen atom or a protective group of a terminal alkyne, from mannose, comprising the following steps: (a) protecting the 5 hydroxyl groups of the mannose by a protective group P; (b) coupling the protected mannose obtained at step (a) with a compound of the following formula (II). The present invention also relates to a compound of formula (IIIa).
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: January 24, 2023
    Assignee: ENTEROME
    Inventors: Denis Viktorovich Arefyev, Michael P. Cruskie, Chaminda Priyapushpa Gamage, Joseph Chase Chewning, Marc Labelle
  • Patent number: 11555082
    Abstract: The present invention pertains to: a p-boronophenylalanine derivative that comprises a polymer to which a group represented by formula (I) is linked directly or via a linker; a composition containing same; and a kit for producing said derivative and composition.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: January 17, 2023
    Assignee: TOKYO INSTITUTE OF TECHNOLOGY
    Inventors: Nobuhiro Nishiyama, Takahiro Nomoto, Yukiya Inoue, Ying Yao, Kaito Kanamori, Hiroyasu Takemoto, Makoto Matsui, Keishiro Tomoda
  • Patent number: 11547685
    Abstract: This document provides methods and materials for treating polycystic diseases such as polycystic kidney disease. For example, methods for using a TRPV2 agonist (e.g., probenecid) and optionally a vasopressin receptor antagonist (e.g., tolvaptan) to treat a mammal having polycystic kidney disease (e.g., autosomal dominant polycystic kidney disease) are provided.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: January 10, 2023
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Vicente E. Torres, Fouad T. Chebib, Peter C. Harris, Xiaofang Wang
  • Patent number: 11541019
    Abstract: This invention relates to compositions for use in the treatment of diabetes, for example type-2 diabetes; obesity; and/or metabolic syndrome. Specifically, the invention relates to a composition for use in the treatment of diabetes, the composition comprising at least one of diindolylmethane; indole-3-carbinol; embelin; [6]-gingerol; and [6]-shogaol, or combinations each thereof. Also disclosed is use in the treatment of obesity and use in the treatment of metabolic syndrome.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: January 3, 2023
    Assignee: University of Ulster
    Inventors: Aine Maire McKillop, Peter Raymond Flatt
  • Patent number: 11540551
    Abstract: An energy composition includes a methylated xanthine, a choline derivative, and at least one flavorant in a sufficient amount to render the energy composition palatable. The energy composition may also include vitamins, amino acids, enzymes, preservatives, and the like.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: January 3, 2023
    Assignee: International IP Holdings LLC
    Inventor: Manoj Bhargava
  • Patent number: 11529325
    Abstract: The subject invention provides therapeutic compositions and uses thereof for improving pulmonary function. In one embodiment, the therapeutic composition comprises one or more free amino acids selected from lysine, glycine, threonine, valine, tyrosine, aspartic acid, isoleucine, tryptophan, asparagine, and serine; and electrolytes. In one embodiment, the subject invention can be used to prevent or treat long-term lung complications induced by radiation.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: December 20, 2022
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventors: Sadasivan Vidyasagar, Paul Okunieff
  • Patent number: 11529365
    Abstract: A method and composition including an effective amount of one or more synthetic neutral HMOs are disclosed for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation and for improving one or more gastrointestinal conditions.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: December 20, 2022
    Assignee: Glycom A/S
    Inventors: Bruce McConnell, Louise Kristine Vigsnæs
  • Patent number: 11524017
    Abstract: The present disclosure relates to, inter alia, a method of treating cancer in a human patient in need thereof, comprising administering a therapeutically effective amount of a substrate of AKR1B1, AKR1B10, or both to said patient, wherein said patient has, or is suspected to have, cancer cells with elevated levels of AKR1B1, AKR1B10, or both, wherein said substrate is not 2-deoxy-D-glucose.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: December 13, 2022
    Assignee: Beijing Normal University Hong Kong Baptist University United International College
    Inventors: Stephen Chung, Shiqing Zhang
  • Patent number: 11510932
    Abstract: A composition and method for the treatment of Alzheimer's disease and related amyloid plaque development and reduction of amyloid plaque, amyloidosis and amyotrophic lateral sclerosis, includes an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, being administered to a person in an amount from about 0.5 grams to about 18.75 grams per day.
    Type: Grant
    Filed: October 6, 2020
    Date of Patent: November 29, 2022
    Inventor: Robert Sabin
  • Patent number: 11491176
    Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.
    Type: Grant
    Filed: February 21, 2022
    Date of Patent: November 8, 2022
    Assignee: IVERIC bio, Inc.
    Inventors: Samir Patel, Richard Everett, Douglas Brooks, Shane Xinxin Tian
  • Patent number: 11491093
    Abstract: The invention relates to compositions comprising certain sorbitan carboxylic esters and glycerol carboxylic esters in particular amounts.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: November 8, 2022
    Assignee: Evonik Operations GmbH
    Inventors: Kathrin Daniela Brandt, Dominik Schuch, Beata Bednorz
  • Patent number: 11492353
    Abstract: Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: November 8, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Richard L. Mackman, Jay P. Parrish, Adrian S. Ray, Dorothy Agnes Theodore
  • Patent number: 11486005
    Abstract: The present disclosure provides methods for determining whether a patient exhibiting cystic fibrosis symptoms, or a patient at risk for cystic fibrosis, will benefit from treatment with one or more anti-cystic fibrosis therapeutic agents. These methods are based on detecting hereditary cystic fibrosis related mutations in small-volume dried biological fluid samples that are collected using a volumetric absorptive microsampling device. Kits for use in practicing the methods are also provided.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: November 1, 2022
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Heather Sanders, Nigel J. Clarke
  • Patent number: 11452682
    Abstract: A toothpaste composition for alleviating dentin hyperesthesia is disclosed. The composition includes a peptide consisting of an amino acid sequence of the following Formula 1: K-Y-R1-R2-R3-R4-R5-R6-R7-R8??(Formula 1) wherein R1 is arginine (R), lysine (K) or glutamine (Q); R2 is arginine (R) or glutamine (Q); R3, R4, and R5 are arginine (R) or lysine (K), respectively; R6 is asparagine (N) or serine (S); and R7 and R8 are lysine (K) or tyrosine (Y), respectively.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: September 27, 2022
    Assignee: HYSENSBIO
    Inventors: Joo Hwang Park, Ji Hyun Lee
  • Patent number: 11433087
    Abstract: The disclosure provides a CD169 high affinity anti-tumor compound (TCC-Neu5A) and its preparation and application. The CD169 high affinity anti-tumor compound is a small molecule compound, which has specific and broad-spectrum tumor killing characteristics. TCC-Neu5Ac could targets tumor cells in vivo and metabolize onto a surface of the tumor cells to form CD169 ligands. These tumor cells are recognized and phagocytized by CD169-positive macrophages, which then release tumor-related antigens and present them to other immune cells, triggering an anti-tumor immune response. The CD169 high affinity anti-tumor compound provided by the disclosure is effective for a variety of tumors and has an inhibitory effect on tumor metastasis. In addition, the CD169 high affinity anti-tumor compound provided by the disclosure can not only be injected but also be orally administered. Cytotoxicity and animal toxicity of the CD169 high affinity anti-tumor compound are very low.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: September 6, 2022
    Assignee: Xiamen Nuokangde Biological Technology Co., Ltd.
    Inventors: Xu Yan, Xuchun Han, Xianwu Wang
  • Patent number: 11433045
    Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, and/or Syndrome X (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such a
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: September 6, 2022
    Inventors: Saskia Kley, Dania Reiche
  • Patent number: 11427555
    Abstract: Shown and described are improved processes for the preparation of dapagliflozin of Formula I, or its solvates or co-crystals thereof and intermediates and their use in the preparation of dapagliflozin of Formula I or its solvates or co-crystals thereof.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: August 30, 2022
    Assignee: Laurus Labs Limited
    Inventors: Uma Maheswar Rao Vasireddi, Sanjay Kumar Dehury, Madana Venkata Sudhakar Gutti, Krishna Murthy Thopudurthi
  • Patent number: 11426386
    Abstract: A method of treating cardiovascular disorders and diseases in a subject in need thereof includes administering to the subject an ADH inhibitor, AKR inhibitor, and/or SNO-CoAR inhibitor at an amount(s) effective to promote S-nitrosylation of proteins in the subject, wherein the ADH inhibitor and/or SNO-CoAR inhibitor is not an ADH3 inhibitor.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: August 30, 2022
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventor: Jonathan S. Stamler
  • Patent number: 11420972
    Abstract: Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: August 23, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Richard L. Mackman, Jay P. Parrish, Adrian S. Ray, Dorothy Agnes Theodore
  • Patent number: 11413298
    Abstract: The present invention provides a pharmaceutical composition for use in prevention or treatment of a human rhinovirus (HRV) infection. The composition comprises an aldohexose, wherein the hydroxyl group at carbon 2 of the aldohexose is replaced by any one of H, F, Cl, Br, I, SH, Me, OMe and SMe, such as a 2-deoxy-glucose. Furthermore, a dispenser for intranasal administration, such as a nasal spray or nose drop applicator containing said pharmaceutical composition is provided. In addition, an inhalation device, such as a metered-dose inhaler, a dry-powder inhaler or a nebuliser, comprising said composition is provided.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: August 16, 2022
    Assignee: MEDIZINISCHE UNIVERSITAT WIEN
    Inventors: Johannes Stockl, Guido Gualdoni
  • Patent number: 11369664
    Abstract: The present disclosure is concerned with compositions comprising insulin and a pharmaceutically acceptable topical carrier. The present disclosure is also concerned with methods of using these compositions for the treatment of a skin ailment such as a diabetic ulcer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: June 28, 2022
    Assignee: Eleos Pharmaceuticals, Inc.
    Inventors: Mona E. Buice, David M. Sailors, Joshua Z. Greeson
  • Patent number: 11340226
    Abstract: The present invention provides a method for providing a diagnosis or prognosis of a non-alcoholic fatty liver disease (NAFLD) in a subject by detecting expression level of the Squalene Epoxidase (SQLE) gene. A kit and device useful for such methods are also provided. In addition, the present invention provides a method for treating NAFLD by suppressing SQLE gene expression or activity.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: May 24, 2022
    Assignee: The Chinese University of Hong Kong
    Inventors: Jun Yu, Dabin Liu, Chi-Chun Wong
  • Patent number: 11338023
    Abstract: There is provided a composition including parietal polysaccharides from at least one Candida species and parietal polysaccharides from at least one different yeast species. The composition can be used in modulating and/or stimulating immune responses in animal or human.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: May 24, 2022
    Assignee: DANSTAR FERMENT AG
    Inventor: Mathieu Castex
  • Patent number: 11311556
    Abstract: The invention features topical dutasteride emulsions for local delivery to the dermis of a subject suffering from hair loss, such as hair loss secondary to endocrine therapy in patients with breast cancer.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: April 26, 2022
    Assignee: Varsona Therapeutics, Inc.
    Inventors: Vinay Kumar Jindal, Manu Gujrati, Mary Angelica Oba Magsombol-Karaan
  • Patent number: 11304966
    Abstract: The application relates to synthetic compositions and methods for preventing or reducing nociception and/or nociceptive sensitivity in a non-infant human. The human is administered a composition comprising 6?-sialyllactose (6?-SL) and/or lacto-N-tetraose (LNT).
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: April 19, 2022
    Assignee: Glycom A/S
    Inventors: Bruce McConnell, Louise Kristine Vigsnæs, Sami Damak, Norbert Sprenger, Francis Foata
  • Patent number: 11278557
    Abstract: The invention belongs to the field of biomedicine, and particularly relates to a glucose core, comprising a glucose and/or a glucose hydrate, a diluent and a binder, wherein, the glucose and/or the glucose hydrate is present in the glucose core in an amount of ?85% by weight percentage; and relates to a glucose pellet comprising the glucose core and a laminated layer coating the glucose core; and further relates to a pharmaceutical composition comprising the glucose pellet. The glucose pellet or the pharmaceutical composition of the invention are useful in treatment and/or assistant treatment of a glycogen storage disease and/or a diabetes.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: March 22, 2022
    Assignee: COSCI MED-TECH CO. LTD.
    Inventors: Changqing Zhang, Dezhi Zhu, Shenghai Zhang, Jie Ning, Xiaoyan Xian
  • Patent number: 11260032
    Abstract: A nano drug delivery system includes a biofilm-coated drug nanocrystal. A drug in a physical form of nanocrystal is directly used as a rigid supporting skeleton, and is filled in a biofilm. The nano drug delivery system has the advantages of high drug loading capacity, good biocompatibility, long systemic circulation time and drug sustained release.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: March 1, 2022
    Assignee: Shanghai Whittlong Pharmaceutical Institute
    Inventors: Weiyue Lu, Zhilan Chai, Xuefeng Hu, Cao Xie, Huimin Hou, Hao Wang
  • Patent number: 11260096
    Abstract: Disclosed herein are methods for creatine supplementation for human subjects, particularly creatine non-responders.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: March 1, 2022
    Assignee: ThermoLife International, LLC
    Inventors: Ronald Kramer, Alexandros Nikolaidis
  • Patent number: 11241420
    Abstract: The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents, and treating or preventing addictive or compulsive behaviour and relapse practice of an addictive behaviour or compulsion, by administering a peroxisome proliferator-activated receptor gamma (PPAR?) agonist, alone or in combination with another therapeutic agent, such as, for example, an opioid receptor antagonist or an antidepressant, or an addictive agent, such as, for example, an opioid agonist. The present invention also includes pharmaceutical compositions for treating or preventing addiction or relapse that include a PPAR? agonist and one or more other therapeutic or addictive agents, as well as unit dosage forms of such pharmaceutical compositions, which contain a dosage effective in treating or preventing addiction or relapse.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: February 8, 2022
    Assignee: Omeros Corporation
    Inventor: Roberto Ciccocioppo
  • Patent number: 11225500
    Abstract: The invention relates to a process for the manufacture of the crystalline compound according to formula (I) comprising the steps (a) deacetylating the final intermediate (FI), (b) forming the crystalline compound according to formula (I) by reacting the deacetylated final intermediate of step (a) with L-proline and water and isolating the final reaction product; processes of manufacturing intermediates thereof; process intermediates and their uses in the processes according to the present invention.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: January 18, 2022
    Inventors: Matthias Eckhardt, Monika Brink, Frank Himmelsbach, Stefan Sahli, Chutian Shu, Xiao-Jun Wang, Beat Theodor Weber, Bing-Shiou Yang
  • Patent number: 11220516
    Abstract: The present disclosure provides for modified antibiotic compounds, methods of making modified antibiotic compounds, methods of use, products including modified antibiotic compounds, and the like. The modified antibiotic compound comprises a nitric oxide release agent covalently attached to an antibiotic molecule, such as S-nitroso-N-acetylpenicillamine covalently attached to ampicillin.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: January 11, 2022
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Hitesh Handa, Sean P. Hopkins, Priyadarshini Singha, Christina Danielle Workman
  • Patent number: 11202798
    Abstract: The present invention is directed to methods for treating or ameliorating skin conditions, diabetic conditions, cardiovascular conditions, cancer, infections or metal poisoning, enhancing performance, or providing nutritional support, comprising administering to a subject in need thereof compositions comprising a magnetic dipole stabilized solution (MDSS). The MDSS solution may include additional components and can be provided in a kit.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: December 21, 2021
    Assignee: REVEN PHARMACEUTICALS, INC.
    Inventors: Peter Lange, Brian Denomme, Henk Van Wyk, Mariette Van Wyk, Tracy L. Krebs, Sezgin Ozgur, Zishan Haroon
  • Patent number: 11191835
    Abstract: The present disclosure relates to novel chlorin-vitamin conjugates and method of making and using the chlorin-vitamin conjugates.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: December 7, 2021
    Assignee: Purdue Research Foundation
    Inventor: Meden Fruel Isaac-Lam
  • Patent number: 11179364
    Abstract: The disclosure concerns the use of LIK066 in the treatment, prevention or delay of non-alcoholic steatohepatitis.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: November 23, 2021
    Assignee: Novartis AG
    Inventors: Lloyd Klickstein, C. Daniel Meyers, Chinweike Ukomadu
  • Patent number: 11180788
    Abstract: The present invention discloses a method for preparing lower graft degree GSGs, and belongs to the technical field of biosynthesis of sweeteners. The method uses amylase to catalyze hydrolysis of GSGs with a high graft degree, thereby obtaining GSGs with low graft degree mainly containing GSGs with a low grafting number. The content of mono- and di-glucosyl substituents in the SGs in the product was 60% or more of the total glycosides, and the mass percent of the GSGs with a glucosyl grafting number of 3 or less was higher than 70% of the total glycosides. The mono- and di-substituted GSGs obtained by enzyme catalysis by the present invention were structurally similar to those, belong to a mixture of the isomers thereof, and have good sweetness and a flavoring function.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: November 23, 2021
    Assignees: Jiangnan University, Dongtai Haorui Biotechnology Co., Ltd.
    Inventors: Yongmei Xia, Liping Zhu, Tongtong Zhang, Guoying Du, Xiang Liu, Yun Fang
  • Patent number: 11141450
    Abstract: A method for enhancing at least one of craving-reduction, mood improvement, avoidance of depression, prevention of weight gain post weight-loss from dieting, reduction of negative side effects produced by anti-appetite drugs and smoke-cessation and promotion of healthy ageing in a person in need thereof, comprising administering a composition to said person, said composition comprising: a) an effective amount of an extract of Cyperus esculentus peel, Cyperus esculentus rhizomes, or a combination thereof; b) an effective amount of mangiferin, norathyriol, or an extract comprising mangiferin or norathyriol; or c) a synergistic combination of (a) and (b). The composition may comprise a third active ingredient in combination with the Cyperus esculentus extract and mangiferin or norathyriol.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: October 12, 2021
    Assignee: NEKTIUM PHARMA, S.L.
    Inventors: Miguel Jiménez del Río, Julia C. Wiebe, Laura López-Ríos, Tanausú Vega Morales, Rubén Peréz Machín, Alvaro Sánchez Rodríguez, Carlos J. Mateos, Nigel Peter Gericke
  • Patent number: 11129401
    Abstract: Provided herein is a method of improving the taste profile of a glucosylated terpene glycoside (GTG) comprising: a) mixing a malted cereal with a glucosylated terpene glycosides in water to form a GTG cereal mixture wherein the cereal comprises an amylase; b) adjusting the temperature of the mixture to a temperature sufficient to activate the amylase and for a time sufficient to form a mixture comprising glycosylated steviol glycosides wherein the average number of glucose units of the GTG in the GTG cereal mixture is reduced.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: September 28, 2021
    Assignee: Firmenich SA
    Inventors: Wen-Juan Xiang, Dan-Ting Yin, Olivier Haefliger
  • Patent number: 11102994
    Abstract: Provided herein are beverage compositions to be ingested by a patient prior to administration of anesthesia or sedation comprising: a) one or more carbohydrates, wherein the total Calories available from the carbohydrates is at least about 200 and wherein the one or more carbohydrates are the sole source of significant Calories in the beverage; b) an acid, in a quantity sufficient to result in a pH of at least about 3.7 to about 4.5 and to enhance the shelf life and flavor of the beverage; c) a central nervous system (CNS) stimulant that is also a cerebro-vasoconstrictor; d) a sweetener and e) water, wherein the beverage composition, when ingested at least about two hours prior to administration of anesthesia or sedation is effective to relieve one or more symptoms associated with prolonged fasting. Further provided herein are methods of using the pre-operative beverage compositions disclosed herein in preparation for the safe induction of anesthesia or sedation in a patient before surgery.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: August 31, 2021
    Assignee: CLEARFAST INC.
    Inventor: M. Lou Marsh
  • Patent number: 11103433
    Abstract: Compositions comprising one or more chelating agents and optionally zinc ion salts are used to inhibit the growth or biofilm formation in bacteria associated with personal care products such as ophthalmic, pedicure, manicure or podiatric solutions. The compositions of the present application can also comprise gelling agents, antimicrobials, antibiotic or a pH adjuster. The compositions may be in the form of a solution, a gel, a cream, a jelly, a powder, a paste, a lotion, soap and a cleaner.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: August 31, 2021
    Assignee: KANE BIOTECH INC.
    Inventors: Purushottam V. Gawande, Karen Lovetri, Nandadeva Yakandawala, Gord Froehlich, Srinivasa Madhyastha
  • Patent number: 11090287
    Abstract: A pharmaceutical composition or dietary supplement with antioxidant activity, mood-regulating activity and insulin-sensitizing activity, with a consequent reduction of the accumulation of adipose tissue, is described, for use in the prevention and treatment of metabolic disorders associated with menopause and climacteric. The composition of the invention comprises, as active ingredients, a combination of alpha-lipoic acid, curcumin and L-tryptophan.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: August 17, 2021
    Assignee: Kolinpharma S.p.A.
    Inventors: Domenico Bijno, Carmine Di Vincenzo, Emanuele Lusenti, Alberto Martina, Ritapaola Petrelli
  • Patent number: 11090323
    Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: August 17, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Uli Christian Broedl, Sreeraj Macha, Maximilian von Eynatten, Hans-Juergen Woerle
  • Patent number: 11084842
    Abstract: A glucopyranosyl derivative as a sodium-dependent glucose transporters inhibitor, especially as a SGLT1 inhibitor, a pharmaceutically acceptable salt or a stereoisomer thereof, a pharmaceutical composition thereof, and the uses of the compound and pharmaceutical composition thereof in the preparation of drugs for the treatment of diabetes and diabetes-related diseases.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: August 10, 2021
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Zheng Gu, Wuyong Wu, Tong Qu, Panpan Kang, Zongyuan Zhang, Weiming Huang, Jianyu Liu, Yingjun Zhang
  • Patent number: 11077078
    Abstract: The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I wherein X is selected from the group consisting of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide, and amine oxide; and R is selected from the group consisting of: OR?, N(R?)2, C(O)R??, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, a C6-C12 heteroaryl, H, and an alkali metal; where R? represents H, alkali metal, C1-C6 alkyl, C6-C12 aryl or C(O)R??, R? represents H, C1-C6 alkyl, or C6-C12 aryl, and R?? represents H, C1-C20 alkyl or C6-C12 aryl. The anti-cancer composition can additionally comprise at least one sugar, which stabilizes the cellular energy inhibitor by substantially preventing the inhibitor from hydrolyzing. Also, the anti-cancer composition can comprise a hexokinase inhibitor.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: August 3, 2021
    Assignee: KoDiscovery, LLC
    Inventor: Young Hee Ko
  • Patent number: RE49080
    Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: May 24, 2022
    Assignee: Novartis AG
    Inventors: Gregory Raymond Bebernitz, Mark G. Bock, Dumbala Srinivas Reddy, Atul Kashinath Hajare, Vinod Vyavahare, Sandeep Bhausaheb Bhosale, Suresh Eknath Kurhade, Videsh Salunkhe, Nadim S. Shaikh, Debnath Bhuniya, P. Venkata Palle, Lili Feng, Jessica Liang